Data from EMC - Curated by Toby Galbraith - Last updated 09 June 2017

Licensing authority

EMA (European Medicines Agency)


Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).

NovoEight can be used for all age groups.

Full Prescribing information

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.

Visit Oral Anticoagulation Reversal

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

Visit Acute and Advanced Heart Failure

Related Content

More information

Category Value
Agency product number EMEA/H/C/002719
Orphan designation No
Date First Approved 13-11-2013
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Novo Nordisk A/S

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reacti